Embedded Files
1. NAME OF THE MEDICINAL PRODUCT
Procto-Glyvenol, 400 mg + 40 mg, suppository
Procto-Glyvenol, 5% + 2%, rectal cream
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
• One suppository (2 g) contains 400 mg of tribenoside and 40 mg of lidocaine.
• 1 g of rectal cream contains 50 mg of tribenoside and 20 mg of lidocaine hydrochloride.
Excipients with known effect:
Rectal cream: methyl parahydroxybenzoate, propyl parahydroxybenzoate, cetyl alcohol.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
• Suppositories: Yellowish-white, torpedo-shaped suppositories free from fissures, solid, slightly greasy.
• Rectal cream: White, homogeneous cream, with a mild characteristic odour.
4. CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
Local treatment of external and internal haemorrhoids.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
One suppository should be administered or the rectal cream applied morning and evening until acute
symptoms have diminished, after which the dosage can be reduced to once a day.
Paediatric population
There is no clinical experience with tribenoside and lidocaine Rectal cream and Suppository
in children.
4.3. CONTRAINDICATIONS
Hypersensitivity to the active substances or to any of the excipients of tribenoside and lidocaine Rectal
cream and Suppository listed in section 6.1.
4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients with hepatic impairment
Tribenoside and lidocaine Rectal cream and Suppository should be used with precaution in patients
suffering from severe hepatic damage.
Paediatric population
There is no clinical experience with tribenoside and lidocaine Rectal cream and Suppository in children.
Information concerning excipients
Tribenoside and lidocaine rectal cream contains:
• cetyl alcohol which may cause local skin reactions (e.g. contact dermatitis).
• methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions
(possibly delayed).
Contact with the eyes should be avoided.
The product must not be swallowed.
4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No interaction studies have been performed.
4.6. FERTILITY, PREGNANCY AND LACTATION
Pregnancy and breast-feeding
There are no controlled studies on the potential effects of tribenoside and lidocaine in pregnant or
lactating women. As a precaution, tribenoside and lidocaine Rectal cream and Suppository should not be
used during the first 3 months of pregnancy.
Tribenoside and lidocaine Rectal cream and Suppository may be used as from the 4th month of pregnancy
and during breast-feeding, however the recommended dosing should not be exceeded.
Fertility
Animal studies indicate that lidocaine does not have effects on fertility.
No data is available on the potential effects of tribenoside on fertility.
4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
Tribenoside and lidocaine Rectal cream and Suppository have no or negligible influence on the ability to
drive and use machines.
4.8. UNDESIRABLE EFFECTS
Summary of the safety profile
Rare reported adverse reactions during treatment are local reactions like burning (application site pain),
rash and pruritus which may spread beyond the application site. Beside these undesirable effects, the
administration of tribenoside and lidocaine Rectal cream and Suppository may trigger in very rare cases
an anaphylactic reaction including possible symptoms (e.g. angioedema and face edema).
Tabulated list of adverse reactions
Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very
common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <
1/1,000); very rare (< 1/10,000), or not known (cannot be estimated from the available data). Within each
frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Description of selected adverse reactions
Anaphylactic reactions may very rarely occur, including angioneuronic edema, face edema,
bronchospasm and cardiovascular disorders.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions is an important way to gather more information to continuously
monitor of the benefit/risk balance of the medicinal product. Any suspected adverse reactions should be
reported to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs, Fax: + 357
22608649.
4.9. OVERDOSE
There is no experience of overdosage with tribenoside and lidocaine Rectal cream and Suppository.
In case of accidental oral ingestion gastric lavage is recommended together with symptomatic treatment
and general supportive measures.
5. PHARMACOLOGICAL PROPERTIES
5.1. PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Antihemorrhoidals for topical use. ATC code: C05A D Products containing
local anaesthetics.
Mechanism of action
Tribenoside reduces capillary permeability and improves vascular tone. It also has anti-inflammatory
properties and exerts an antagonistic action on a number of endogenous substances, which play a role as
mediators in the development of inflammation and pain.
Lidocaine is a local anaesthetic, which relieves itching, smarting and pain caused by haemorrhoids.
5.2 PHARMACOKINETIC PROPERTIES
Absorption
The systemic bioavailability of tribenoside from suppositories amounts to only 30% of that attained when
the substance is given orally or intravenously. Between 2-20% of the tribenoside contained in the cream is
absorbed through the skin. Peak plasma concentrations of 1 microgram/ml (tribenoside & metabolites)
were recorded 2 hours after rectal administration of 1 suppository (400 mg tribenoside).
Lidocaine is absorbed readily from mucous membranes and poorly from intact skin. Its bioavailability is
about 50% after rectal administration. Peak plasma concentrations of only 0.70 microgram/ml were
recorded 112 minutes after administration of 1 suppository of as much as 300 mg lidocaine.
Distribution
Lidocaine is markedly bound to alpha1-acid glycoprotein.
Biotransformation
Tribenoside is extensively metabolized in the body. Lidocaine is rapidly metabolized in the liver.
Elimination
Tribenoside: 20-27% of the dose administered by suppository is excreted in the urine in the
form of metabolites.
Lidocaine metabolites are excreted in the urine with less than 10% of unchanged lidocaine.
5.3 PRECLINICAL SAFETY DATA
Tribenoside:
Non-clinical acute and repeated dose toxicity studies with tribenoside showed the product to be
practically non-toxic by oral administration. Reproduction toxicity studies are not available. Rectal
application produces effective local concentrations with minimal systemic exposure and is, therefore, not
expected to produce a toxicological profile different from oral tribenoside.
Lidocaine:
In animal studies the toxicity noted after overdosage of lidocaine consisted of effects on the central
nervous and cardiovascular systems. No drug-related adverse effects were seen in reproduction toxicity
studies, neither did lidocaine show a mutagenic potential in either in vitro or in vivo mutagenicity tests.
6. PHARMACEUTICAL PARTICULARS
6.1. LIST OF EXCIPIENTS
• Suppository: Hard fat N°1 (Witepsol E85), Hard fat N° 2 (Witepsol W35)
• Rectal Cream: Macrogol cetostearyl ether (Cetomacrogol 1000), Cetyl alcohol, Isopropyl palmitate,
Liquid paraffin, Methyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sorbitan stearate (Arlacel
60), Sorbitol liquid (non crystallising), Stearic acid, Purified water.
6.2. INCOMPATIBILITIES
Not applicable.
6.3. SHELF LIFE
• Suppository: 5 years
• Rectal cream: 5 years
6.4. SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 30°C.
Store in the original package.
6.5. NATURE AND CONTENTS OF CONTAINER
• Suppository: box of 10, sealed in polyethylene and polypropylene laminated aluminium foil.
• Rectal cream: 30 g, aluminium tube with an inner coating made of epoxy-phenol resin lacquer, a
polyethylene cap, a latex joint and a polyethylene nozzle.
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING
No special requirements.
7. MARKETING AUTHORISATION HOLDER
Recordati Hellas Pharmaceuticals SA.
7, Zoodochou Pigis Street 15231,
K. Chalandri, Athens,
Greece
8. MARKETING AUTHORISATION NUMBER(S)
Cream: 17441
Suppositories: 18327
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
Cream: 13 November 1997/ 20 June 2008
Suppositories: 24 August 1999/ 20 June 2008
10. DATE OF REVISION OF THE TEXT
6 October 2015
Google Sites
Report abuse